Developing a mechanistic model of IVT to include nucleation and growth of magnesium pyrophosphate crystals and subsequent agglomeration of crystals and DNA.
Nathan Stover
PhD Student, Chemical Engineering
Massachusetts Institute of Technology
Michael Steinbaugh
Director, Data, AI & Genome Sciences
Merck
David Kombo
Principal Scientist
Sanofi
Justin Scheer
Vice President, In Silico Discovery
Johnson & Johnson Innovative Medicine
Morten Sogaard
Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma
Philip Tagari
Chief Scientific Officer
Insitro
Forges powerful ecosystems by aligning pharma, tech, and academia, enabling shared expertise and resources to accelerate breakthroughs and navigate complex R&D challenges.
Explore how machine learning techniques, such as supervised learning and deep learning, predict critical ADME properties like solubility, permeability, and DDI risk.
Discover how computational methods, including molecular docking and quantum chemistry simulations, optimize high-affinity drug-target interactions for enhanced efficacy.
Attila Csikász-Nagy
CEO
Cytocast
Attila is a visionary leader with a strong background in computational and systems biology. As a professor and researcher, he has made significant contributions to the field, with an impressive publication record and expertise in bioinformatics. With experience at renowned institutions like Microsoft Research and King's College London, Attila brings a unique blend of scientific knowledge and business management skills to his role as CEO. In addition to his professional pursuits, Attila enjoys playing basketball competitively with his old high school friends.
David Kombo
Principal Scientist
Sanofi
Jacob Berlin
CEO
Terray Therapeutics
Cytocast
Website: https://www.cytocast.com/
Cytocast, a TechBio startup based in Budapest, Hungary, accelerates drug discovery by combining bioinformatics, AI, and large‑scale digital‑twin simulations to predict side effects at the start of R&D. Pharma, biotech and CRO teams use the Cytocast technology to de‑risk portfolios earlier and focus resources on safer candidates.
The CYTOCAST DIGITAL TWIN Platform™ models cellular systems to deliver breadth‑first side‑effect profiling for early‑stage small‑molecule programs, including combinations. Proteome‑based simulations reveal how candidates perturb cellular processes and provide actionable evidence to refine chemistries and improve safety. The platform has been validated through pilots with small and mid‑size partners. Currently, the following products are available for the clients’ tailored needs:
- Cytocast Screener™: Rank thousands of compounds by likely side effects to guide early discovery.
- Cytocast Optimizer™: After in vitro/in vivo, refine leads with comparative safety insights for preclinical decisions.
- Cytocast Nominator™: In‑depth analyses to support final candidate selection for trials.
Cytocast has raised €2.5M pre‑seed to date. We are opening a new €5M seed to expand product capabilities and market reach with the goal of adoption at least 10 top‑100 pharma companies by 2027. Cytocast is a proud member of the Alliance for Artificial Intelligence in Healthcare (AAIH) and NVIDIA Inception.
Lana Garmire
Associate Professor
University of Michigan
Safeguards the innovation pipeline by proactively securing sensitive research data, enhancing risk resilience and ensuring stakeholder confidence in the integrity of AI-driven discoveries.